Premium
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia
Author(s) -
Kantarjian Hagop,
Talpaz Moshe,
O'Brien Susan,
Giles Francis,
Beth Rios Mary,
White Kevin,
GarciaManero Guillermo,
Ferrajoli Alessandra,
Verstovsek Srdan,
Wierda William,
Kornblau Steven,
Cortes Jorge
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11381
Subject(s) - imatinib mesylate , medicine , chronic myelogenous leukemia , philadelphia chromosome , imatinib , cytogenetics , oncology , leukemia , gastroenterology , immunology , chromosome , chromosomal translocation , biology , myeloid leukemia , genetics , gene
BACKGROUND Obtaining a major (Philadelphia chromosome [Ph] of < 35%) or a complete cytogenetic response (Ph of 0%) has been associated with excellent long‐term survival. Cytogenetic response may continue to improve with therapy. Because early allogeneic stem cell transplantation (SCT) may be associated with a better outcome, early parameters predicting for subsequent cytogenetic responses would optimize the treatment decision‐making. METHODS The current study was performed to analyze whether early cytogenetic responses may be predictive of later major or complete cytogenetic responses to imatinib mesylate therapy in patients with Ph‐positive chronic myelogenous leukemia (CML). RESULTS Two hundred sixty‐one patients with Ph‐positive, chronic‐phase CML after failure with interferon therapy who were treated with imatinib mesylate therapy were analyzed. A persistence of 100% Ph‐positive cells after ≥ 6 months of imatinib mesylate therapy was associated with a major cytogenetic response rate of 9–13% and a complete cytogenetic response rate of 0–4%. However, a minor cytogenetic response after 3–12 months of therapy still was associated with high rates of major (68–83%) or complete (35–54%) cytogenetic response rates. CONCLUSIONS Patients with Ph‐positive, chronic‐phase CML who have persistent 100% Ph‐positive disease after ≥ 6 months of imatinib mesylate therapy may be offered allogeneic SCT or considered for alternative investigational therapies. Cancer 2003;97:2225–8. © 2003 American Cancer Society. DOI 10.1002/cncr.11381